BIND Stock News 8.87 05/13/2014 17:46:30 Bind Therapeutics Inc

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bind Therapeutics Inc (BIND) 8.87 $BIND

BIND Therapeutics Reports First Quarter 2014 Financial Results and Updates BIND-014 Clinical Development Plan
Business Wire - Thu May 08, 6:30AM CDT
--- Management to host conference call today at 8:30 am ET -

BIND Therapeutics to Present at UBS Global Healthcare Conference
Business Wire - Mon May 05, 7:30AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the UBS Global Healthcare Conference in New York on Monday, May 19, 2014 at 11:00 a.m. ET.

BIND Therapeutics to Report First Quarter 2014 Financial Results on May 8, 2014
Business Wire - Thu May 01, 7:30AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced it will report first quarter 2014 financial results on Thursday, May 8, 2014. BIND's management team will host a conference call and audio webcast at 8:30 a.m., Eastern Time on Thursday, May 8, 2014 to discuss the quarterly results and recent business developments.

BIND Therapeutics Presents Clinical Data Highlighting Unique Attributes of Lead Cancer Drug Candidate, BIND-014, at AACR 2014 Annual Meeting
Business Wire - Mon Apr 07, 3:01PM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that clinical data on its lead drug candidate, BIND-014, were presented at the American Association of Cancer Research (AACR) meeting. The clinical data from a completed Phase 1 study demonstrate differentiating attributes of BIND-014 administered with a weekly dosing schedule which may enable increased dose intensity and enhanced therapeutic efficacy of BIND-014. In addition, data supporting the potential utility of PSMA as a target and marker for BIND-014 patient selection were presented.

Company news for March 26, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 9:06AM CDT
Companies in the News are: CCL,BIND,MKC,WAG

BIND Therapeutics, Inc. [BIND] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Tue Mar 25, 10:21AM CDT
What:

BIND Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Tue Mar 25, 6:30AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today reported financial results for the fourth quarter and year-ended December 31, 2013.

BIND Therapeutics to Ring the NASDAQ Stock Market Opening Bell on March 26, 2014
Business Wire - Wed Mar 19, 7:30AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced that Company management will ring the Opening Bell at the NASDAQ MarketSite in Times Square, New York at 9:30 a.m. ET on Wednesday, March 26, 2014. A live webcast will be available at https://new.livestream.com/nasdaq/live.

BIND Therapeutics to Report Fourth Quarter and Year End 2013 Financial Results and Business Developments on March 25, 2014
Business Wire - Tue Mar 18, 7:30AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced it will report fourth quarter and year ended December 31, 2013 financial results on Tuesday, March 25, 2014. BIND's management team will host a conference call and audio webcast at 8:30 a.m., Eastern Time, on Tuesday, March 25, 2014 to discuss the quarterly results and recent business developments.

BIND Therapeutics to Present Data at the AACR 2014 Annual Meeting
Business Wire - Wed Mar 05, 7:30AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that three poster presentations including clinical data on its lead drug candidate, BIND-014 and preclinical data on its AstraZeneca collaboration based on Barasertib (AZD1152), will be presented at the upcoming American Association of Cancer Research (AACR) meeting which takes place April 5-9, 2014 in San Diego, CA.

BIND Therapeutics Promotes Key Executives: Organization Positioned for Continued Growth
Business Wire - Mon Mar 03, 3:15PM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced that it has structured its management team for future growth by promoting and expanding the areas of responsibility for members of its management team. Andrew Hirsch has been appointed Chief Operating Officer with expanded responsibilities, including program and alliance management and oversight of BIND's Russian operations. Andrew will continue to serve as Chief Financial Officer of the company. Jeff Hrkach, Ph.D., formerly Senior Vice President, Technology Research and Development, has been promoted to Chief Technology Officer with responsibility for the research, development and manufacturing of BIND's Accurin pipeline and research and technology development related to BIND's Medicinal Nanoengineering(R) platform.

BIND Therapeutics to Present at 26th Annual Roth Conference
Business Wire - Wed Feb 26, 7:30AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the 26th Annual Roth Conference in Laguna Nigel, CA on Monday, March 10, 2014 at 11:30 a.m. PT.

BIND Therapeutics to Present at Cowen 34th Annual Healthcare Conference
Business Wire - Mon Feb 24, 8:04AM CST
BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the Cowen 34th Annual Healthcare Conference in Boston on Tuesday, March 4, 2014 at 10:40 a.m. ET.

3 Biotech Stocks Rising on Big Volume
at The Street - Tue Feb 11, 5:00AM CST
Keep these biotech stocks trading on unusual volume on your radar.

Concise Analysis of the Opportunities in the International Graphene Industry
M2 - Mon Feb 03, 4:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/krkmk8/the_graphene) has announced the addition of the "Concise Analysis of the Opportunities in the International Graphene Industry" report to their offering. A decade ago when the first edition of the Nanotechnology Opportunity Report was published, there were predictions of untold riches for early investors, the replacement of all manufacturing as we know it, and the mythical trillion-dollar market. The author went against the grain by predicting that it would be hard for anyone to make money from nanomaterials, and that the real value would be in the applications. This has been borne out by the failure of even large global companies such as Mitsubishi Chemical and Bayer to make much headway with fullerenes and carbon nanotubes, and the failure of countless smaller nanomaterials producers. On the other hand companies making use of nanomaterials, Germany's Magforce Technologies and the US based BIND Therapeutics have shown what can be achieved when nanomaterials are applied to large addressable markets, in this case drug delivery. Is Graphene The New Nanotech? A similar amount of hype currently surrounds graphene, with wild predictions of applications ranging from microelectronics to water treatment. This report examines these claims and taking the rational approach for which the author is known, considers how valid these are and evaluates the chances of success. The author also looks in detail at the graphene producers. Graphene comes in a wide range of forms, each with its own particular set of addressable applications. No one producer covers all applications and many are destined to be niche players. As with nanomaterials, many companies currently producing graphene are destined to burn brightly and then be unceremoniously snuffed out when scale up or access to applications fails to materialise. Key Topics Covered: Introduction A Brief History of Carbon Nanomaterials Can Graphene Succeed Where Fullerenes Failed? Types of Graphene Large-Scale Production Applications of Graphene The Graphene Opportunity Advanced Materials Structural Composites Microelectronics Key Applications Photonics & Optoelectronics For more information visit http://www.researchandmarkets.com/research/kr...e_graphene

BIND Therapeutics to Present at February Healthcare Conferences
Business Wire - Tue Jan 28, 7:30AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the following healthcare conferences during February 2014:

Nasdaq stocks posting largest percentage decreases
AP - Wed Jan 08, 12:32PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:

Why BIND Therapeutics Inc. Shares Soured
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 08, 11:54AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of BIND Therapeutics , a clinical-stage...

BIND Therapeutics Announces Departure of Chief Medical Officer
Business Wire - Tue Jan 07, 3:00PM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced that Greg Berk, M.D., Chief Medical Officer, will be leaving BIND to pursue another opportunity. Dr. Berk will serve as an advisor to BIND after his departure.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 53

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 141

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 144

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 163

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 82

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
TIER IV Simplifies Autonomous Driving with CARLA 1.0

Updated Category News Views 38

No More Detours in Autonomous Development Ever messed with a puzzle that just won't fit until suddenly, it clicks? That's what TIER IV just pulled off with their latest work on CARLA 1.0, the open-source simulator. There's no more mucking about with that separate Python-based bridge to get things communicating—now we're talking native Autoware support. A direct line to...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 91

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionary Prostate Treatment Program Launches in Dallas

Updated Category News Views 191

Transforming Prostate Care with the TULSA Program The landscape of prostate treatment is evolving, thanks to the groundbreaking advancements brought forth by Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) and its launch of the TULSA program in collaboration with Texas Prostate and Dallas Medical Center. This pioneering initiative aims to cater to the rising need for...

Continue Reading
Addex Expands Share Capital for Future Financial Flexibility

Updated Category News Views 254

Recent Developments at Addex Therapeutics Ad Hoc Announcement Addex Therapeutics, a clinical-stage biopharmaceutical firm, has made a significant move by issuing 34,300,000 new registered shares. These shares, issued by Addex Pharma S.A, a wholly-owned subsidiary, allow the company to strategically increase its issued share capital to CHF 2,186,544.96. This adjustment...

Continue Reading
Jasper Therapeutics Receives Major Boost from Oppenheimer's $80 Target

Updated Category News Views 130

Oppenheimer Affirms Positive Outlook for Jasper Therapeutics Jasper Therapeutics (NASDAQ:JSPR) has recently captured the attention of investors, particularly following Oppenheimer's announcement of its continued support with an Outperform rating and a notable price target set at $80. The positive sentiment originates from the recent findings of a Phase 1b/2a clinical...

Continue Reading
Taylor Morrison Launches New Resort Community Near Jacksonville

Updated Category News Views 286

Taylor Morrison Launches New Resort Community Near Jacksonville In an exciting development for homebuyers, Taylor Morrison, recognized as one of America’s Most Trusted® Home Builders, has officially broken ground on its first resort lifestyle community in the Jacksonville area. This ambitious project, named Esplanade at St. Marys, spans an impressive 1,250 acres and is...

Continue Reading
Middlefield Canadian Income PCC Report: NAV Insights

Updated Category News Views 123

Understanding Middlefield Canadian Income PCC's Financial Position Middlefield Canadian Income PCC is a notable player in the investment landscape, focusing on generating sustainable income from a diversified portfolio. Understanding its net asset value (NAV) is crucial for investors looking to gauge the company's financial stability and growth potential. Current Net...

Continue Reading